Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Engineered hyaluronic acid hydrogel for enhanced EV retention and controlled release

Obiettivo

Extracellular vesicles (EVs) are rapidly emerging as a next-generation therapeutic modality in regenerative medicine and immunomodulation. However, a major translational limitation is their rapid dispersion and clearance following administration. Existing hydrogel delivery systems typically rely on physical encapsulation in gels developed for other biomedical applications, or chemical/ genetic modification of EVs to tether them to hydrogels to achieve retention. Such approaches lack control over EV release, or can alter EV surface properties, complicate manufacturing, and restrict compatibility to specific EV types. To address this problem, GelEV aims to validate a novel hyaluronic acid (HA)-based hydrogel that enhances EV retention without requiring EV surface modification or encapsulation. This bio- and cyto-compatible platform incorporates hydrogel modifications to prolong local EV availability while preserving native EV structure and function. By avoiding EV modification steps, the system is designed to be compatible with diverse EV sources and manufacturing pipelines. Thus far, this novel hydrogel demonstrates increased retention of murine MSC-derived EVs. This project will de-risk the technology by verifying hydrogel manufacturability and by validating compatibility with clinically relevant human, lyophilised, and commercially available EV formulations. Functional assays will confirm preservation of bioactivity following sustained release. The development of an EV-agnostic hydrogel delivery platform will create an enabling technology for the expanding EV therapeutics sector. If successful, the licensable platform will allow EV developers to enhance therapeutic performance by having a controlled EV delivery tool, without altering their EV products, thereby accelerating clinical translation across multiple regenerative and inflammatory indications for patients, positioning it for commercial adoption in research and pharmaceutical contexts.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2026-POC

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

UNIVERSITY OF GALWAY
Contributo netto dell'UE
€ 150 000,00
Indirizzo
UNIVERSITY ROAD
H91 Galway
Irlanda
Regione
Ireland Northern and Western West
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato

Beneficiari (1)